NXC-201 Receives Orphan Drug Designation in European Union for Multiple Myeloma
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
Source: onclive.com
Nxc 201 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nxc 201. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nxc 201 Today - Breaking & Trending Today
NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis
Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.
Source: onclive.com
Looking Ahead: Future Perspectives on AL Amyloidosis
Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.
Source: onclive.com
European Commission Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis
NXC-201 has received orphan drug designation from the European Commission for use in patients with amyloid light-chain amyloidosis.
Source: onclive.com
Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials
Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.
Source: onclive.com